Parenteral aminoglycoside therapy. Selection, administration and monitoring.

Abstract:

:Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extracellular, but penetration into cerebrospinal fluid and other secretions is meagre. They display trough concentration-dependent reversible nephrotoxicity and The commonly irreversible ototoxicity, which may present after treatment ceases. Gentamicin is the usual all-purpose agent of choice, tobramycin is slightly more effective against Pseudomonas aeruginosa infections, amikacin is the least susceptible to degradation by bacterial enzymes and netilmicin is probably the least toxic. Clinical and drug concentration monitoring have a role in therapy. Aminoglycosides exhibit enduring antibacterial activity (especially against Gram-negative bacilli) many hours after tissue concentrations become negligible. Appreciation of this postantibiotic effect is leading to replacement of conventional multiple daily doses by large single daily doses. The latter regimens confer at least equivalent efficacy and less risk of toxicity (particularly renal). However, single daily dosage may be unsuitable for immunocompromised patients and in those with infective endocarditis, where there is insufficient experience. Cotreatment with beta-lactams is commonly used in order to exploit the synergism between these agents, particularly in enterococcal endocarditis and severe Gram-negative sepsis. Liposomal aminoglycosides are promising parenteral formulations. After being taken up by phagocytes they reach the liver, spleen and sites of inflammation; subsequently they are gradually released. To substantiate the applicability of these hitherto experimental formulations, findings from clinical studies are keenly awaited.

journal_name

Drugs

journal_title

Drugs

authors

Kumana CR,Yuen KY

doi

10.2165/00003495-199447060-00004

subject

Has Abstract

pub_date

1994-06-01 00:00:00

pages

902-13

issue

6

eissn

0012-6667

issn

1179-1950

journal_volume

47

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Almotriptan: a review of its use in migraine.

    abstract:UNLABELLED:Almotriptan is a selective serotonin 5-HT(1B/1D) receptor agonist ('triptan'). Its efficacy and tolerability have been assessed in a number of randomised, controlled trials in over 4800 adults with moderate or severe attacks of migraine. Oral almotriptan has a rapid onset of action (significant headache reli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262020-00010

    authors: Keam SJ,Goa KL,Figgitt DP

    更新日期:2002-01-01 00:00:00

  • Rational use of disease-modifying antirheumatic drugs.

    abstract::The currently available, most frequently used disease-modifying antirheumatic drugs (DMARDs) include auranofin, azathioprine, D-penicillamine, gold sodium thiomalate, hydroxychloroquine, methotrexate (amethopterin) and sulphasalazine. Controlled trials of these agents are reviewed to compare their relative efficacy an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199039010-00003

    authors: Furst DE

    更新日期:1990-01-01 00:00:00

  • Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

    abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0489-4

    authors: Trendowski M

    更新日期:2015-11-01 00:00:00

  • NSAIDs and gastrointestinal cancer prevention.

    abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262060-00006

    authors: Jolly K,Cheng KK,Langman MJ

    更新日期:2002-01-01 00:00:00

  • Cholinesterase inhibitors for Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world. Substantial progress has been made in understanding the basic neurobiology of AD and, as a result, new drugs for its treatment have become available. Cholinestera...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161010-00005

    authors: Grutzendler J,Morris JC

    更新日期:2001-01-01 00:00:00

  • Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

    abstract::Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510040-00001

    authors: Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

    更新日期:1975-01-01 00:00:00

  • The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

    abstract::This paper reviews the use of the fluoroquinolone antibiotics in the management of sexually transmitted diseases (STD) in Southeast Asia. Numerous clinical trials performed in the region have shown that the quinolones are highly effective for treating uncomplicated gonorrhoea. Norfloxacin 800 mg, ofloxacin 400 mg, cip...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00019

    authors: Sivayathorn A

    更新日期:1995-01-01 00:00:00

  • Tocilizumab: a review of its use in the management of rheumatoid arthritis.

    abstract::Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous tocilizumab 8 mg/kg (and no less than 4.8 mg), in combination with methotrexate, is approved in the EU for the treatment of moderate to severe active rheumatoid arthriti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969050-00007

    authors: Oldfield V,Dhillon S,Plosker GL

    更新日期:2009-01-01 00:00:00

  • White coat hypertension and related phenomena. A clinical approach.

    abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00017

    authors: Ocón-Pujadas J,Mora-Maciá J

    更新日期:1993-01-01 00:00:00

  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

    abstract::Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly imp...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363210-00001

    authors: Bradford DW,Perkins DO,Lieberman JA

    更新日期:2003-01-01 00:00:00

  • Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.

    abstract::Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0420-z

    authors: Syed YY,McCormack PL

    更新日期:2015-07-01 00:00:00

  • The use of quinolones in developing countries.

    abstract::The size of the antibiotic market in developing countries is double that seen in developed countries. There are some valid reasons for this difference, one of which is the higher frequency of diverse infections in the developing world. However, other factors are involved: for example, antibiotics are available without...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300453-00009

    authors: Rodríguez-Noriega E,Morfin-Otero R,Esparza-Ahumada S

    更新日期:1993-01-01 00:00:00

  • Oral antidiabetic agents: current role in type 2 diabetes mellitus.

    abstract::Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eve...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565030-00005

    authors: Krentz AJ,Bailey CJ

    更新日期:2005-01-01 00:00:00

  • Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

    abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161140-00011

    authors: Keating GM,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Studies with temocillin in the hamster model of antibiotic-associated colitis.

    abstract::The studies reported here were designed to ascertain whether or not the new beta-lactam antibiotic, temocillin, would produce antibiotic-associated colitis in the hamster. The experiments were controlled with clindamycin and cefoxitin, which are known to induce antibiotic-associated colitis experimentally and clinical...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00012

    authors: Boon RJ,Beale AS

    更新日期:1985-01-01 00:00:00

  • A comparison of roxatidine acetate and ranitidine in gastric ulcer healing.

    abstract::A randomised multicentre double-blind study was conducted to compare the efficacy and safety of roxatidine acetate 75 mg twice daily and ranitidine 150 mg twice daily in 295 patients with endoscopically confirmed gastric ulcers. Substantial reductions in ulcer diameters and healing rates of 85.6 and 88.2% for roxatidi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00021

    authors: Judmaier G

    更新日期:1988-01-01 00:00:00

  • Androgen replacement therapy in androgen-deficient women with hypopituitarism.

    abstract::Hypopituitarism is a rare disorder, but its prevalence has increased as a result of an increase in secondary causes of hypopituitarism such as traumatic brain injury and cranial irradiation. Estrogen with or without progestogen (progestin) treatment is conventional therapy in women with hypopituitarism. Recent data de...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868150-00001

    authors: Zang H,Davis SR

    更新日期:2008-01-01 00:00:00

  • Colloid volume expanders. Problems, pitfalls and possibilities.

    abstract::Colloid solutions have been developed and used over the past 70 years as expanders of the intravascular space, based on an understanding of Starling's law. Increasing osmotic pressure with colloidal products has remained an attractive theoretical premise for volume resuscitation. Indeed, colloids have been shown to in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855050-00002

    authors: Roberts JS,Bratton SL

    更新日期:1998-05-01 00:00:00

  • Etanercept: a review of its use in autoimmune inflammatory diseases.

    abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0258-9

    authors: Scott LJ

    更新日期:2014-08-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

    abstract::Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855040-00002

    authors: Opal SM,Yu RL Jr

    更新日期:1998-04-01 00:00:00

  • Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy.

    abstract::Many drugs have a site of action within the inner ear. The list includes therapeutic, diagnostic and ototoxic agents. Therapeutic agents are most useful in cases of infections, endolymphatic hydrops, vascular insufficiency, vertigo of peripheral origin, autoimmune disease, otosclerosis (otospongiosis), sudden hearing ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836060-00005

    authors: Norris CH

    更新日期:1988-12-01 00:00:00

  • MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

    abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0869-7

    authors: Shirley M,Taha MK

    更新日期:2018-02-01 00:00:00

  • Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

    abstract::Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00001

    authors: Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

    更新日期:1982-09-01 00:00:00

  • Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

    abstract::Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluores...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0409-7

    authors: Keating GM

    更新日期:2015-05-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0634-8

    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01152-7

    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Use of beta-adrenoreceptor blockers in combination with beta-stimulators in patients with obstructive lung disease.

    abstract::Lung function can be reduced not only by a non-selective beta-blocker but also by a selective beta1-receptor blocker. If both types of drug are without intrinsic sympathomimetic activity, the effect of the non-selective drug is more pronounced than that of a beta1-receptor selective drug under basal conditions. The ef...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197600111-00035

    authors: Johnsson G

    更新日期:1976-01-01 00:00:00

  • Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

    abstract::The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00012

    authors: Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

    更新日期:1985-01-01 00:00:00